EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act) Epigenomics AG Launches Colorectal Cancer Blood Test Epi proColon in Europe

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Molecular diagnostics

06.10.2009

Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics
company, today announced, that it launched in Europe a CE-marked, in
vitro diagnostic blood test for early detection of colorectal cancer.
The test, which is marketed under the brand name Epi proColon, is a
molecular diagnostic test that can detect tumor derived methylated
DNA of the Septin9 gene (mSEPT9) in blood plasma as a biomarker for
colorectal cancer. Epi proColon is the first in vitro diagnostic
blood test for the early detection of colorectal cancer that is
available in Europe as CE-marked product in accordance with European
regulations for in vitro diagnostic (IVD) products.

In a performance evaluation study, the final step of Epigenomics' IVD
product development, analyzing blood samples from about 260 patients
with colorectal cancer or without any evidence of colorectal cancer,
the Epi proColon test detected two thirds of the cancer cases in
early, still localized disease stages. When colorectal cancer is
still localized, i.e. has not spread to lymph nodes or distant
organs, about 90% of the patients can be cured from the disease (90%
5-year survival rate). Across all disease stages, the study confirmed
results from previous clinical studies with the mSEPT9 biomarker in
detecting about 70% of all cancer cases at about 90% specificity. The
test aims at patients who should undergo colorectal cancer screening
but reject current methods for colorectal cancer early detection such
as stool tests and invasive colonoscopy.

Epi proColon is the first CE-marked IVD product that Epigenomics
markets directly to molecular diagnostic laboratories in Europe.
Epigenomics aims at serving the home market in Germany, Austria and
Switzerland through direct marketing and sales, while initially
commercializing through distributors in other European markets.

In addition to direct commercialization, Epigenomics continues to
pursue its non-exclusive licensing strategy for its mSEPT9 biomarker
for colorectal cancer blood testing and is working with several
partners in the diagnostics industry. Of these, Abbott Molecular,
Chicago, IL, U.S.A. and Quest Diagnostics, Giralda Farms, NJ, U.S.A.,
are expected to start offering their mSEPT9 tests in Europe and the
U.S.A., respectively, in the fourth quarter of 2009.

End of ad hoc

Further Information

For further information please see today's press release on the
launch of the Epi proColon product at HYPERLINK "http://www.epigenomi
cs.com/en/Newsroom/"http://www.epigenomics.com/en/Newsroom/.
Epigenomics' management will host a conference call for investors and
media on the Epi proColon launch and its strategy going forward at
4pm CET today, Tuesday, October 6, 2009. The dial-in numbers for the
conference call are:

Dial-in number (within Germany): +49 (0)69 247 501 891
Dial-in number (within the US): +1 212 444 0297

Participants are kindly requested to dial in 10 minutes prior to the
start of the call.

The presentation accompanying the conference call will be available
at 3 pm for download on the Epigenomics website:
http://www.epigenomics.com/en/down_loads/corporate_material/

A recording of the conference call will be provided on Epigenomics'
website subsequently:
http://www.epigenomics.com/en/down_loads/corporate_material/

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale in the
United States. The analytical and clinical performance
characteristics of any product based on this technology which may be
sold at some future time in the U.S. have not been established.

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade